Protecting and improving health for a population of approximately half a billion people, equal access to modern and efficient healthcare for all Europeans, disease prevention and response – these are just a few topics on the health agenda of the European Union.

But regarding pharmaceutical R&D, the EU is at risk of losing touch with the rest of the world, says EFPIA, the European Federation of Pharmaceutical Industries and Associations. In an interview with the German news portal Pharma Fakten EFPIA's Director General, Nathalie Moll, demands an “ambitious industrial strategy.”